CL2023001268A1 - Composiciones farmacéuticas de un inhibidor de cinasa - Google Patents
Composiciones farmacéuticas de un inhibidor de cinasaInfo
- Publication number
- CL2023001268A1 CL2023001268A1 CL2023001268A CL2023001268A CL2023001268A1 CL 2023001268 A1 CL2023001268 A1 CL 2023001268A1 CL 2023001268 A CL2023001268 A CL 2023001268A CL 2023001268 A CL2023001268 A CL 2023001268A CL 2023001268 A1 CL2023001268 A1 CL 2023001268A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical compositions
- kinase inhibitor
- relates
- kinase
- modulating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención hace referncia a composiciones farmacéuticas del inhibidor de c-Met, Compuesto 1. La invención también hace referencia a métodos de tratamiento de una enfermedad, un trastorno o síndrome mediado al menos parcialmente por la modulación de la actividad in vivo de una proteína cinasa con la composición farmacéutica y a procesos para producir las composiciones farmacéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110124P | 2020-11-05 | 2020-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001268A1 true CL2023001268A1 (es) | 2023-12-11 |
Family
ID=78820880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001268A CL2023001268A1 (es) | 2020-11-05 | 2023-05-03 | Composiciones farmacéuticas de un inhibidor de cinasa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230398108A1 (es) |
| EP (1) | EP4240333A1 (es) |
| JP (1) | JP2023548855A (es) |
| KR (1) | KR20230104186A (es) |
| CN (1) | CN116406261A (es) |
| AU (1) | AU2021374669A1 (es) |
| CA (1) | CA3196001A1 (es) |
| CL (1) | CL2023001268A1 (es) |
| CO (1) | CO2023005942A2 (es) |
| CR (1) | CR20230223A (es) |
| IL (1) | IL302485A (es) |
| MX (1) | MX2023005273A (es) |
| PE (1) | PE20240223A1 (es) |
| TW (1) | TW202227061A (es) |
| WO (1) | WO2022098828A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117603138A (zh) * | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221035A (zh) * | 2010-07-16 | 2013-07-24 | 埃克塞里艾克西斯公司 | C-met调节剂药物组合物 |
| EP2981263B1 (en) * | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| CN117603138A (zh) | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| SG11202105949RA (en) | 2018-12-13 | 2021-07-29 | Exelixis Inc | Crystalline forms and salt forms of a kinase inhibitor |
| WO2020135401A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
-
2021
- 2021-11-04 CA CA3196001A patent/CA3196001A1/en active Pending
- 2021-11-04 CR CR20230223A patent/CR20230223A/es unknown
- 2021-11-04 PE PE2023001561A patent/PE20240223A1/es unknown
- 2021-11-04 KR KR1020237017606A patent/KR20230104186A/ko unknown
- 2021-11-04 EP EP21819284.7A patent/EP4240333A1/en active Pending
- 2021-11-04 JP JP2023526968A patent/JP2023548855A/ja active Pending
- 2021-11-04 US US18/035,355 patent/US20230398108A1/en active Pending
- 2021-11-04 IL IL302485A patent/IL302485A/en unknown
- 2021-11-04 MX MX2023005273A patent/MX2023005273A/es unknown
- 2021-11-04 CN CN202180074166.6A patent/CN116406261A/zh active Pending
- 2021-11-04 AU AU2021374669A patent/AU2021374669A1/en active Pending
- 2021-11-04 WO PCT/US2021/057996 patent/WO2022098828A1/en active Application Filing
- 2021-11-05 TW TW110141305A patent/TW202227061A/zh unknown
-
2023
- 2023-05-03 CL CL2023001268A patent/CL2023001268A1/es unknown
- 2023-05-09 CO CONC2023/0005942A patent/CO2023005942A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230398108A1 (en) | 2023-12-14 |
| KR20230104186A (ko) | 2023-07-07 |
| CN116406261A (zh) | 2023-07-07 |
| CA3196001A1 (en) | 2022-05-12 |
| AU2021374669A9 (en) | 2024-04-18 |
| IL302485A (en) | 2023-06-01 |
| EP4240333A1 (en) | 2023-09-13 |
| CR20230223A (es) | 2023-07-07 |
| PE20240223A1 (es) | 2024-02-16 |
| AU2021374669A1 (en) | 2023-06-15 |
| TW202227061A (zh) | 2022-07-16 |
| MX2023005273A (es) | 2023-05-23 |
| JP2023548855A (ja) | 2023-11-21 |
| WO2022098828A1 (en) | 2022-05-12 |
| CO2023005942A2 (es) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| CL2021001537A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| CO2021017343A2 (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| ECSP22091485A (es) | Imidazolpiridazinas como moduladores de il-17 | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| BR112022006016A2 (pt) | Métodos e materiais para tratar neurotoxicidade | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| BR112019002204A2 (pt) | reelin composições para tratamento de problemas neurológicos | |
| CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma | |
| BR112023026971A2 (pt) | Sirna para inibir expressão do gene angptl3 e usos do mesmo | |
| BR112021025907A2 (pt) | Método para aumentar o efeito de uma composição de neurotoxina botulínica e composição | |
| BR112022024700A2 (pt) | Inibidores de atr e usos dos mesmos | |
| BR112022015869A2 (pt) | Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto | |
| BR112023020649A2 (pt) | Composição para tratamento de superfície queratinosa |